Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01FOM
|
|||
| Former ID |
DNC010248
|
|||
| Drug Name |
4-(piperazin-1-yl)thieno[2,3-d]pyrimidine
|
|||
| Synonyms |
4-(piperazin-1-yl)thieno[2,3-d]pyrimidine; 373356-48-0; 1-{thieno[2,3-d]pyrimidin-4-yl}piperazine; 4-piperazin-1-ylthieno[2,3-d]pyrimidine; CHEMBL596108; 1-(Thieno[2,3-d]pyrimidin-4-yl)piperazine; AC1Q1I4T; SCHEMBL4922800; CTK7D1707; MolPort-001-760-894; ZINC12954996; SBB095996; BDBM50304810; AKOS000123564; MCULE-6714459164; PS-3311; NE24045; KS-000029X0; 4-piperazinylthiopheno[2,3-d]pyrimidine; KB-85055; DA-06355; 4-Piperazin-1-yl-thieno[2,3-d]pyrimidine; KB-243074; FT-0727983; EN300-29445; Thieno[2,3-d]pyrimidine, 4-(1-piperaziny
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H12N4S
|
|||
| Canonical SMILES |
C1CN(CCN1)C2=C3C=CSC3=NC=N2
|
|||
| InChI |
1S/C10H12N4S/c1-6-15-10-8(1)9(12-7-13-10)14-4-2-11-3-5-14/h1,6-7,11H,2-5H2
|
|||
| InChIKey |
HFGUINASBGDWLY-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 373356-48-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 2C receptor (HTR2C) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Gap junction | ||||
| Serotonergic synapse | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | 5HT2 type receptor mediated signaling pathway | |||
| Reactome | Serotonin receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.